Deborah Dunsire has more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bringing a breadth of scientific and business experience. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc. Deborah joined Lundbeck as President & CEO in September 2018.
Deborah graduated from University of the Witwatersrand, South Africa in 1985 and is trained as a medical doctor.
Deborah serves as a Member of the Board of Alexion Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
Peter Anastasiou began his career in the pharmaceutical industry at Eli Lilly in 1992, where he stayed for more than 11 years. He then moved on to senior positions in Bristol-Myers Squibb and Neuronetics, Inc. before joining Lundbeck in 2009. Peter has held several positions within Lundbeck’s psychiatry and neurology franchises. Since 2016, he has been President of Lundbeck North America overseeing the operations of both the U.S. and Canadian businesses.
Peter holds a bachelor in economics and management from Albion College and an MBA in general management from Indiana University – Kelly School of business.
Peter is a Member of the Board of Bear Necessities Pediatric Cancer Foundation and PhRMA (Pharmaceutical Research and Manufacturers of America).
Having completed his degree, Lars Bang began his career at Lundbeck in 1988 as a trainee in R&D. Subsequently, he has head R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A, Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering.
Lars holds a Master of Science degree in Engineering from the Technical University of Denmark and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School.
Lars is a Member of the Board of Claudio Bidco A/S, Claudio Holdco A/S, Fertin Pharma A/S and OB Holding.
After finishing his education, Anders Götzsche joined PwC in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 Anders held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007 as Chief Financial Officer.
Anders holds a Master of Science in Accounting from University of Southern Denmark (1991), and he became a state-authorized public accountant in 1997.
Anders is the Chairman of the Board of Rosborg Møbler A/S and serves on the Board of Directors of Veloxis Pharmaceutical A/S, where he chairs the Audit Committee.
Anders further serves on the Board of Directors of DFDS A/S, where he also chairs the Audit Committee.
Elise brings close to 20 years of global and strategic people development across a broad spectrum of companies and industries. She joins Lundbeck from SimCorp, a financial technology company, as Senior Vice President and Chief Human Resources Officer since 2014. Elise started her career working with insurance and pension in the financial industry at Nordea and moved to Microsoft, where she lived in Seattle for a period of time. Before SimCorp Elise held senior HR positions in Nycomed, Switzerland, and was part of the Takeda acquisition and integration.
Elise holds a Masters in Law from the University of Copenhagen.
Keld Flintholm Jørgensen began his career at Arthur Andersen Corporate Assurance Services in Copenhagen. In 2000, he moved to F. Hoffmann La Roche’s headquarter in Basel, Switzerland, where he held different roles within Group risk management and Strategic Planning for the Pharma Division. In 2005, he relocated to the Baltics and became part of the leadership team responsible for established the first Roche sales affiliates in the region. Subsequently, he returned to Switzerland as Head of Finance and Business Partnering for the Swiss sales affiliate. From 2011, he moved to Roche Pharma Partnering as Director Strategic Partnering and successfully executed multiple strategic projects, partnering agreements and M&A deals across different therapy areas, including neuroscience. In 2017, he was promoted to Global Head Strategic Partnering at Roche and a member of the Late Stage Portfolio Committee. In April 2019, he joined Lundbeck as Executive Vice President and Chief Business Officer.
Keld holds a BSc in Economics & Business Administration and a MSc in Business Economics & Auditing from Copenhagen Business School.
In 1991, Johan Luthman began his career in the pharmaceutical industry in Astra, later AstraZeneca. In 2005, Johan became Head of Neuroscience Research at Merck Serono. In 2009, he became CEO of biotech start-up GeNeuro. From mid-2009 Johan joined Merck as VP & Franchise Integrator for Neuroscience and Opthamology. In 2014, he came to Eisai where he was Senior Vice President and Head of Clinical Development. Johan joined Lundbeck as Executive Vice President, R&D in March 2019.
Johan is a Swedish national and is trained as a Doctor of Dental Sciences from the Karolinska Institute, Sweden. He further holds a PhD in Neurobiology and Histology also from the Karolinska Institute, Sweden.
Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in several positions including Finance, Investor Relations and Corporate Communication and has worked in Lundbeck’s affiliate in the US for approximately four years.
Before taking on the role as Executive Vice President, Commercial Operations, Jacob was head of Corporate Functions which comprised of Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs.
Jacob holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.